Healthcare · NYSE/NASDAQ: DXCM
DEXCOM INC
Medical Devices
Market Cap $28.64B
Verdict: Exceptional
Quality Scores
Multi-Bagger
89/100
Compounder Quality
94/100
Management Credibility
93/100
Governance
92/100
Cash Flow Quality
98/100
AI Summary
Dexcom has transitioned from a niche medical device manufacturer to a dominant global force in Continuous Glucose Monitoring (CGM) systems. Over the last decade, the company achieved an extraordinary revenue CAGR, scaling from roughly $171 million to over $4.6 billion. While early years were marked by heavy R&D investment and net losses, the company reached a critical inflection point in 2019, consistently generating positive net income and robust free cash flow thereafter. Its market leadership is underpinned by the G6 and G7 platforms, which have expanded the addressable market from Type 1…
Top Opportunities
- Explosive 10-year revenue CAGR of ~39%
- Consistent positive Cash Flow from Operations (CFO)
- Strong pivot from net losses to sustained profitability after 2018
Top Risks
- Intense competition from Abbott (Freestyle Libre) and Medtronic
- Pricing pressure as CGM becomes a commodity in some segments
- Significant volatility in Net Income due to non-cash items
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.